StockData
Exelixis, Inc. logo

Exelixis, Inc. (EXEL) stock

EXELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends January 1
Financials through Q3 FY2026, quarter ended Oct 2, 2026Last filing: 10-Q on Oct 29, 2026Score 18/302% above fair value
$64.63−1.20 (-1.82%)

Close on Nov 20, 2026Market cap $15.77BP/E 19.4Yield –

Exelixis shares outstanding

Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.

Exelixis's shares outstanding was 256M at Oct 2, 2026. For fiscal 2025 it was 282M, down 4.8% from the year before. Over ten years it grew 3.0% a year on average. The highest annual figure on record is 325M in fiscal 2022.

Annual shares outstanding

PeriodPeriod endValueChange
FY2025Jan 2, 2026282M-4.8%
FY2024Jan 3, 2025296M-7.9%
FY2023Dec 29, 2023321M-1.0%
FY2022Dec 30, 2022325M+0.7%
FY2021Dec 31, 2021322M+1.4%
FY2020Jan 1, 2021318M+0.9%
FY2019Jan 3, 2020315M+0.7%
FY2018Dec 28, 2018313M+0.3%
FY2017Dec 29, 2017312M+24.5%
FY2016Dec 31, 2016251M+19.7%
FY2015Dec 31, 2015209M+7.7%
FY2014Dec 31, 2014194M+5.6%
FY2013Dec 31, 2013184M+14.9%
FY2012Dec 31, 2012160M+22.7%
FY2011Dec 31, 2011130M+20.2%
FY2010Dec 31, 2010109M+1.4%
FY2009Dec 31, 2009107M–

Quarterly shares outstanding

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Oct 2, 2026256M-8.2%
Q2 FY2026Jul 3, 2026260M-8.7%
Q1 FY2026Apr 3, 2026267M-7.2%
Q4 FY2025Jan 2, 2026276M-5.9%
Q3 FY2025Oct 3, 2025279M-4.4%
Q2 FY2025Jul 4, 2025284M-3.3%
Q1 FY2025Apr 4, 2025288M-5.7%
Q4 FY2024Jan 3, 2025294M-6.2%
Q3 FY2024Sep 27, 2024291M-8.7%
Q2 FY2024Jun 28, 2024294M-10.2%
Q1 FY2024Mar 29, 2024306M-6.4%
Q4 FY2023Dec 29, 2023313M-3.7%
Q3 FY2023Sep 29, 2023319M-1.8%
Q2 FY2023Jun 30, 2023327M+0.7%
Q1 FY2023Mar 31, 2023326M+0.9%
Q4 FY2022Dec 30, 2022325M+0.6%
Q3 FY2022Sep 30, 2022325M+0.9%
Q2 FY2022Jul 1, 2022325M+0.6%
Q1 FY2022Apr 1, 2022323M+0.6%
Q4 FY2021Dec 31, 2021323M+1.1%
Q3 FY2021Oct 1, 2021322M+4.2%
Q2 FY2021Jul 2, 2021323M+1.5%
Q1 FY2021Apr 2, 2021321M+1.7%
Q4 FY2020Jan 1, 2021320M+1.5%
Q3 FY2020Oct 2, 2020309M-2.0%
Q2 FY2020Jul 3, 2020318M+1.0%
Q1 FY2020Apr 3, 2020316M+0.4%
Q4 FY2019Jan 3, 2020315M+1.1%
Q3 FY2019Sep 27, 2019315M+1.0%
Q2 FY2019Jun 28, 2019315M+0.9%
Q1 FY2019Mar 29, 2019315M+0.3%
Q4 FY2018Dec 28, 2018312M-0.6%
Q3 FY2018Sep 28, 2018312M-0.2%
Q2 FY2018Jun 29, 2018312M+0.3%
Q1 FY2018Mar 30, 2018314M+1.3%
Q4 FY2017Dec 29, 2017313M+8.8%
Q3 FY2017Sep 30, 2017313M–
Q2 FY2017Jun 30, 2017311M–
Q1 FY2017Mar 31, 2017310M–
Q4 FY2016Dec 31, 2016288M–

More Exelixis figures

See a number that looks wrong?